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Signs & Symptoms
Systemic Lupus Erythematosus is difficult to diagnose as 
many symptoms are non-specific, including fatigue, joint pain 
and fever (Weinstein, 2012, p. 38). A comprehensive history 
and physical assessment should be performed by a healthcare 
practitioner to determine possible risk for SLE (Weinstein, 
2012, p. 39). Early screening and diagnosis, as well as, 
appropriate risk factor management strategies have improved 
long-term patient outcomes. Progressive treatment plans for 
patients with SLE has improved life expectancy and quality of 
life (Turano, 2013, p. 48). Cardiovascular disease and 
atherosclerosis are becoming the leading cause of death 
amongst patients with SLE and have been attributed to the new 
successful treatment options and improved life expectancy 
(Gilbert & Ryan, 2014, p. 1902). Healthcare providers should 
focus on patient education regarding increased risk for 
cardiovascular disease associated with SLE and risk factor 
management (Weinstein, Amirkhosravi, Angelopoulos, Bushy, 
Covelli & Dennis, 2014, p. 137).
Systemic lupus erythematosus (SLE) is a challenging auto-immune disorder 
that incurs sporadic flares, remissions, and relapses (Robinson & Currie, 2011, p. 
629). This auto-immune process is caused by the lack of tolerance to self-antigens 
within the adaptive immune system and can involve multiple organ systems, 
including the brain, heart and kidneys (Chen, Wu, Wang, Li, 2015, p. 1). SLE, also 
referred to as lupus, is a disease that affects women more often than men, 
especially during their childbearing years (Robinson & Currie, 2011, p. 631).
Over the past 3 decades, the five-year survival rate for patients suffering from 
Lupus have increased from 50% to 95% with decreasing deaths from infection 
and renal disease (Weinstein et al., 2014, p. 130). Cardiovascular disease, 
however, continues to be a main cause of death for those diagnosed from SLE 
(Gilbert & Ryan, 2014, p. 1902). The cardiovascular system is known to be a 
potential target for patient with lupus, causing 7- to 10-fold increase in 
cardiovascular disease (CVD) (Weinstein et al., 2014, p. 130). Complications of 
CVD include pericarditis, valvular and atherosclerotic changes. Women with SLE, 
however, are unaware of the increased risk of cardiovascular disease associated 
with lupus (Weinstein et al., 2014, p.130).
SLE can be masked by the signs and symptoms of other superficial disease 
processes, while the underlying etiology is auto-immune (Weinstein, 2012, p. 38). 
Understanding the pathophysiology of SLE can aid in early diagnosis and 
treatment to provide better long-term patient outcomes and improve quality of 
life. 
Four of the following symptoms must be present for the formal diagnosis of 







• Persistent protein in the urine
• Seizures or psychosis
• Blood disorders: anemia, leukopenia, lymphopenia, thrombocytopenia
• Immunologic disorders: positive anti-double-stranded DNA (anti-
dsDNA), anti-Sm, antiphospholipid antibodies (aPL)
• Positive antinuclear antibody (ANA) test
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Conclusion
 According to the CDC (2015), prevalence and incidence rates for SLE are difficult to predict due to the non-specific nature of presenting 
symptoms. Prevalence rates have varied in the United States from 161,000 to 1.5 million cases. Family history is a strong predictive value 
for development of lupus with more than 20 different genetic abnormalities identified (Weinstein, 2012, p. 40).
 Auto-antibodies in patients with SLE are thought to be the initial causative agent associated with endothelial damage (Turano, 2013, p. 
50). Several different auto-antibodies have been identified in the pathogenesis of SLE, including anti-dsDNA, antiphospholipid (aPL), anti-
Sm and ANA (Weinstein, 2012, p. 42).
 Overexpression of antibody adhesion molecules promotes endothelial damage, leading to atherosclerosis (Tsokos, 2011, p. 2112). The 
extent of atherosclerosis is directly correlated to the duration of SLE symptoms (Turano, 2013, p. 49)
 Epigenetic changes can alter the functionality of T cells and instigate the auto-immune response in SLE (Moulton & Tsokos, 2015, p. 
2225). According to Moulton & Tsokos (2015), hypomethylation of numerous genes, including CD11A, perforin, CD70, and CD40L, have 
been implicated in the development of SLE (p. 2225).
 The focus of treatment is associated with limiting the effect of inflammation on local tissues to prevent damage with non-steroidal anti-
inflammatory drugs (NSAIDS), corticosteroids, antimalarial and immunosuppressive agents (Turano, 2013, p. 49).
The pathophysiology of SLE occurs at both the cellular and tissue level. The cellular level refers to the production and 
tolerance of auto-antibodies. The clinical manifestations of SLE occur at the tissue level by the formation of immune 
complexes that accumulate and deposit in organ tissues.  
Pathophysiology
Understanding the pathophysiology of auto-immune 
disorders, such as SLE, aids in the screening, diagnosis and early 
treatment to decrease the progression of SLE. Using solely the 
traditional Framingham risk factors for cardiovascular disease in 
patients with SLE is ineffective in providing appropriate 
preventative therapy (McMahon et al., 2014, p. 131). 
Healthcare professionals should screen for cardiovascular risk 
factors in patients with SLE, including (Turano, 2013, p. 51): 
 Hypertension 
 Dyslipidemia 
 Diabetes Mellitus 
 Obesity
 SLE disease activity 
 Renal function
 Antiphospholipid or lupus anticoagulant levels
Preventative screenings provide better identification of high 
risk patients and enable early preventative care. In addition, 
education should be provided to all patients regarding the risk of 
cardiovascular disease. Focus should be placed upon modifiable 
risk factor management of blood pressure, weight, smoking 
status, and activity level.  
Treatment using aggressive blood pressure management 
should be maintained in patients with SLE. Use of a multi-drug 
regimen, including angiotensin-converting enzyme (ACE) 
inhibitors, and thiazide diuretics, may be necessary to control 
hypertension (Turano, 2013, p. 52).  The use of beta-blockers can 
precipitate Raynaud’s phenomenon in patients with SLE and 
should be utilized only as a second-line treatment (Turano, 2013, 
p. 51). Corticosteroids are considered to be the gold standard 
treatment in SLE. Long-term use of corticosteroids, however, 
increases the risk of developing insulin resistance and obesity, 
thereby, increasing the risk of cardiovascular disease (Turano, 
2013, p. 51). Utilizing individualized plans of care better tailor 
treatment to each patient with SLE, improving the efficacy of 
treatment and prolonging the progression of SLE.  
SLE can be difficult to diagnose as many symptoms are vague and non-specific, 
such as fatigue, joint pain, fever and recurrent infections. Females are at a higher 
risk of developing SLE than males by a 9:1 ratio (Weinstein, 2012, p. 39). 
Currently, there is no formal diagnostic test for SLE, however, the American 
College of Rheumatology have developed a list of criteria to help diagnose 
patients with lupus. 
Figure 1. Malar Rash
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Cellular level.
 Abnormal activation of T and B cells, along with altered 
signaling events within the cell are characteristic in those 
with SLE (Tsokos, 2011, p. 2111). 
 Signaling abnormalities within the cell lead to a deficiency 
of the interleukin-2 (IL-2) cytokine, causing a decrease in 
efficacy of the cytotoxic T-cell and a decrease in apoptosis 
of the auto-reactive T cells (Tsokos, 2011, p. 2111). 
 T cells migrate to inflamed areas of the body and have a 
heightened expression of the CD44 adhesion molecules, 
facilitating attachment to the endothelial lining of the 
blood vessel (Tsokos, 2011, p. 2112).  
 Plasma cells are responsible for antibody production and 
are increased during the active stage of SLE (Tsokos, 
2011, p. 2112).  An increased production of auto-reactive 
antibodies correlates to the expression/flares of SLE. 
 The immune response is limited/controlled by the 
expression of Treg cells. Patients with SLE have decreased 
and/or dysfunctional Treg cells, which contribute to the 
pathogenesis of SLE (Moulton & Tsokos, 2015, p. 2224).
Tissue level.
 SLE is referred to as a type III hypersensitivity with the 
production of immune complexes that are deposited into 
peripheral tissues. Immune complexes are composed of 
multiple auto-antibodies and self-antigens that are 
circulating within the blood stream (Liao, Reihl, & Luo, 
2016, p. 1). 
 Once the immune complexes are deposited into the 
tissues, the compliment system is activated which 
ultimately instigates the innate inflammatory response 
and promotes tissue damage (Liao, Reihl, & Luo, 2016, p. 
1).
Figure 2. Pathophysiology of SLE
(Tsokos, 2011, p. 2112)
Significance of Pathophysiology
